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Abstract
The mechanism for inflammation associated tumor development is a central issue for tumor biology and immunology and
remains to be fully elucidated. Although IL-17 is implicated in association with inflammation mediated carcinogenesis,
mechanisms are largely elusive. In the current studies, we showed that IL-17 receptor-A gene deficient (IL-17R-/-) mice were
resistant to chemical carcinogen-induced cutaneous carcinogenesis, a well-established inflammation associated tumor
model in the skin. The deficiency in IL-17R increased the infiltration of CD8+ T cells whereas it inhibited the infiltration of
CD11b+ myeloid cells and development of myeloid derived suppressor cells. Inflammation induced skin hyperplasia and
production of pro-tumor inflammatory molecules were inhibited in IL-17R-/- mice. We found that pre-existing inflammation
in the skin increased the susceptibility to tumor growth, which was associated with increased development of tumor
specific IL-17 producing T cells. This inflammation induced susceptibility to tumor growth was abrogated in IL-17R-/- mice.
Finally, neutralizing IL-17 in mice that had already developed chemical carcinogen induced skin tumors could inhibit
inflammation mediated tumor progression at late stages. These results demonstrate that IL-17 mediated inflammation is an
important mechanism for inflammation mediated promotion of tumor development. The study has major implications for
targeting IL-17 in prevention and treatment of tumors.
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Introduction
Immune surveillance mechanisms exist to recognize and
eliminate tumor cells. Defects in immune surveillance are
associated with tumor progression [1,2,3]. In anti-tumor immune
responses, activated T cells infiltrate into tumors and destroy
tumor cells either by cytotoxic effects or elicitation of inflammatory
reactions that will involve other leukocytes in the eradication of
tumors [4,5]. However, chronic inflammation, an unsolved
immune response, promotes tumor development [6,7]. The
infiltration of immune T cells within tumors, no matter at what
stages of tumor development, is associated with beneficial
prognosis [8]. In contrast, infiltration of granulocytes and
macrophages has been considered as a promotion factor in tumor
development [9,10]. Intense inflammatory infiltrates comprised of
large numbers of macrophages and granulocytes and high
concentrations of inflammatory cytokines are characteristics of
tumor promoting inflammation. They are considered to be the
primary tumor promoting factors responsible for enhanced
angiogenesis and cell growth [11].
IL-17 is an important cytokine responsible for inflammatory and
autoimmune diseases [12,13]. Although IL-17 producing cells are
detected in cancer patients and tumor bearing animals [14,15],
studies which mostly use implanted tumor models show a
controversial role of IL-17 in tumor development [14,16].
Accumulating evidence indicates that IL-17 has tumor promoting
effects, especially in the context of inflammation [17,18,19].
However, mechanisms for IL-17 mediated tumor promoting
inflammation remains to be fully elucidated.
Dimethylbenz[a]anthracene (DMBA)-initiated and 12-O-tetrade-
canoylphorbol-13-acetate (TPA)-promoted cutaneous carcinogenesis
is a well-established animal model for inflammation associated tumor
development. The two-stage chemical carcinogenesis protocol
includes single exposure to the mutagen DMBA followed by repeated
application of the inflammation-inducing TPA. Skin lesions can be
followed from premalignant papilloma formation to progression to
carcinoma [20,21,22]. Although the effects of TPA are pleiotropic, its
pro-inflammatory effects arecrucial to tumor promotion. In mice that
are deficient either in inflammatory cytokines IL-1b or TNF-a,
DMBA/TPA induced carcinogenesis is inhibited [23,24]. The
arachidonic acid/cyclooxygenase (Cox) pathway of inflammation
induction has a critical role in TPA induced tumor promotion
[25,26]. Additionally, S100A8/9, a group of calcium binding
proteins, are critical for the development of chemical carcinogenesis
[27,28]. Mice deficient in the Receptor for Advanced Glycation End-
products, a receptor for S100A8/A9, are resistant to DMBA/TPA
induced carcinogenesis [27]. A defect in S100A9 results in increased
infiltration of CD8+ T cells in tumors [29].
OurpreviousstudyshowedthatCD4+T cellswereprimaryIL-17
producing cells in DMBA/TPA induced cutaneous carcinogenesis
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32126[15]. Moreover, DMBA/TPA induced cutaneous carcinogenesis
was enhanced in TLR4 deficient mice, which is associated with an
increased level of IL-17 [30]. It has been reported that IL-23, a
stimulatory cytokine for IL-17 production, promotes DMAB/TPA
induced carcinogenesis [31] whereas it is inhibited in IL-17-/- mice
[18]. However, mechanisms for IL-17 mediated effects on chemical
carcinogenesis are largely unknown.
In the current studies, we examined DMBA/TPA induced
cutaneous carcinogenesis in mice that were deficient in IL-17R,
IL-12p35, or both IL-17R and IL-12p35. The effect of
inflammation on tumor specific T cells and tumor growth and
the role of IL-17 in tumor progression at the late stage were
determined. Our findings indicate that IL-17 is required for
DMBA/TPA induced carcinogenesis in the skin and that blockade
of IL-17 suppresses inflammation mediated tumor development
and progression.
Results
IL-17R deficient mice are resistant to chemical induced
cutaneous carcinogenesis
DMBA/TPA induced skin carcinogenesis was delayed and the
incidence of tumors was greatly decreased in IL-17R-/- mice
compared to wild type controls (Fig. 1a). Moreover, the tumor
multiplicity was significantly reduced in IL-17R-/- mice (Fig. 1b
and 1c). In p35-/- mice, which had a deficiency in IL-12 but not in
IL-23, tumor multiplicity was significantly increased compared to
wild type controls, although the incidence and kinetic of tumor
development was not affected. However, mice that were deficient
in both IL-17R and p35 genes (IL-17R/p35-/-), were resistant to
tumor development in a similar manner to IL-17R-/- mice. These
results indicate that IL-17 responses are required for DMBA/TPA
induced carcinogenesis in the skin and that the effect of IL-17 on
the chemical induced carcinogenesis is independent of IL-12
signals.
The development of skin tumors in DMBA/TPA treated mice is
dependent on TAP induced tumor promoting inflammation
[15,23]. To examine the effect of IL-17R deficiency on DMBA/
TPA treated skin, mouse skin samples were harvested at the end of
experiments (around 26 weeks) and subjected to immunohisto-
chemical analysis. We found that the immigration of CD11b+ cells
into the DMBA/TPA treated skin tissues was decreased (Fig. 2a).
In contrast, the infiltration of CD8+ T cells was significantly
increased in IL-17R-/- compared to wild type mice. The
deficiency in p35 had little effect on the infiltration of CD11b+
cells and CD8+ T cells. However, similar to IL-17R-/- mice, IL-
17R/p35-/- mice had an increased infiltration of CD8+ T cells
and decreased infiltration of macrophages in the skin compared to
p35-/- mice. The effect appeared to be selective on CD8+ T cells
since the infiltration of CD4+ T cells was not significantly affected
in IL-17R-/- and wild type mice (data not shown). The results
implicate important effects of IL-17 on the inflammatory
environment and CD8+ T cell responses in the skin during
chemical induced carcinogenesis.
To determine whether the deficiency in IL-17 receptor has an
effect on leukocytes in peripheral lymphoid organ, spleen cells
from DMBA/TAP treated mice (26 weeks) were analyzed. Results
showed that the percent and total number of CD4+ and CD8+ T
cells and CD19/B200 double positive B cells were not significantly
affected. However, CD1b/Gr-1 double positive myeloid cells are
significantly decreased in the spleen of IL-17R-/- or p35/IL-
17R-/- mice compared to p35-/- and wild type control animals
(Fig. 2b and 2c).
IL-17R deficiency inhibits TPA induced tumor promoting
inflammation in the skin
In the chemical carcinogenesis model, repeated treatments with
TPA cause chronic inflammation which promotes tumor growth
although no evidence shows that the treatment with TPA alone will
induce carcinogenesis [15,23]. Inflammation induced hyperplasia is
an important mechanism for the development and progression of
tumors [32,33]. To test whether IL-17 regulates the development of
TPA induced tumor promoting inflammation, mice were treated
with TPA every other day for a total of three applications and skin
samples were harvested 24 hours after the last treatment. We found
that TPA induced epidermal hyperplasia was inhibited in IL-
17R-/- mice compared to wild type controls (Fig. 3a). Additionally,
we found that there were fewer CD11b+ macrophages and Gr-1+
granulocytes in the TPA treated skin of IL-17R-/- mice (Fig. 3b).
Moreover, the levels of pro-tumor inflammatory cytokines IL-1b
andTNF-a werereducedintheTPAtreated skinofIL-17R-/-mice
compared to wild type mice (Fig. 3c).
Figure 1. IL-17 receptor deficient mice are resistant to DMBA/TPA induced carcinogenesis. Mice were treated once with DMBA and then
with TPA twice a week, as described in the Materials and Methods. Tumor growth was observed every week. A). Tumor incidence. B). Tumor
multiplicity. C). The number of tumors was analyzed statistically at the end of experiments (26 weeks). The bar graph shows the mean number of
tumors per mouse +/2SEM, n=10, ** p,0.01. Data are representative of two independent experiments.
doi:10.1371/journal.pone.0032126.g001
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the expression of S100A8/A9 in the skin of wild type mice whereas
it was undetectable in IL-17R-/- mice (Fig. 3d). S100A8 and
S100A9, two members of the S100 family of calcium binding
proteins, are abundantly produced during acute and chronic
inflammation and play an important role in inflammation
associated tumor development [27,28]. Similar findings were
observed with Cox-2 and prostaglandin E2 (PGE2), a main
Figure 2. IL-17 has opposing effects on the infiltration of CD11b+ macrophages and CD8+ T cells in DMBA/TPA treated skin. Mice
were treated with DMBA and TPA as described in figure 1 and skin tissues were harvested at the end of the experiment (26 weeks). A). Frozen tissue
sections were stained with CD11b antibodies (brown) and counterstained with hematoxylin (blue, upper panels) or with anti-CD8 antibodies (green)
and counterstained with a fluorescence dye DAPI (blue, lower panel). Photos were taken microscopically (206objective). Numbers of positive cells
were counted microscopically. Islets show the enlarged areas of circled squares with positive cells. Graphs show the mean number of positive cells
per field +/2 SEM, n=10, * p,0.05, ** P,0.01. B). Gr-1 and CD11b double positive cells in spleens were stained with fluorescence labeled antibodies
and positive cells were analyzed in a flow cytometer. The numbers in the right upper quadrant indicate the percent of positive cells in whole spleen
cells. C). Statistical analysis of GR-1/CD11b+ (myeloid derived suppressor cells), CD19/B220+ (B cells), CD8+ and CD4+ T cells in spleens (mean +/2
SEM, n=8, ** P,0.01). Data are representative of two independent experiments.
doi:10.1371/journal.pone.0032126.g002
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TPA induced inflammation and tumor promotion in chemical
induced carcinogenesis [25,26]. The concentration of PGE2 was
significantly higher in the TPA treated skin of wild type mice than
in that of IL-17R-/- mice (Fig. 3e). Interestingly, the deficiency in
IL-17R had different effects on chemokine expression in TPA
treated skin tissues. Chemokines KC, CXCL1, and S100A8/A9,
which regulate myeloid cell migration was reduced in IL-17R-/-
mice. In contrast, chemokines CXCL16, CXCL10 and CXCL9,
which are known for regulation of lymphocytes, were increased
(Fig. 3f). Collectively, tumor promoting inflammation which is
induced by the repeated treatment with TPA is suppressed in IL-
17R-/- mice.
Pre-treatment of skin with TPA enhances the
development of tumor specific IL-17 producing T cells
and increases the susceptibility of mice to tumor growth
in an IL-17 dependent way
Many cancers arise from the site of inflammation, which forms a
microenvironment for tumor growth and progression [7]. In order
to further examine roles of IL-17 in inflammation mediated tumor
Figure 3. The deficiency in IL-17 receptor inhibits TPA induced tumor promoting inflammation in the skin. Mice were treated topically
with TPA every other day for a total of three applications. Skin tissues were harvested 24 hours after the last treatment. A). Paraffin embedded tissue
sections were stained with hematoxylin. Skin samples from naı ¨ve untreated mice served as controls. Dashed lines indicate the border between the
epidermis and dermis. The thickness of epidermis was measured microscopically (n=10). B). Frozen tissue sections were stained
immunohistochemcially with antibodies. CD11b+ (monocytes/macrophages) and Gr-1+ (granulocytes) cells were counted microscopically (n=6).
C) Concentrations of cytokines in the skin lysates were measured by ELISA (n=4). D). S100A8 and S100A9 proteins in the skin lysates were detected
by Western blots using specific antibodies. E). Concentrations of PGE2 in the skin lysates were measured by a PGE2 EIA kit (n=3). F). Expression levels
of mRNA for chemokines and cytokines in the skin lysates were quantified by real time RT-PCR (n=3). Data are representative of 2–3 independent
experiments (mean +/2 SEM, * P,0.05: ** P,0.01).
doi:10.1371/journal.pone.0032126.g003
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with TPA every other day for a total of 5 applications and then
inoculated subcutaneously in the TPA treated skin area with an
immunogenic mouse tumor cell line EG7 which is a mouse
lymphoma cell line (EL4) transfected with ovalbumin (OVA).
Results showed that the pre-treatment with TPA enhanced the
growth of implanted EG7 tumors in wild type mice (Fig. 4a). It
implicates that the pre-existing inflammation makes mice
susceptible to tumor development. To examine whether inflam-
mation regulated the development of tumor specific T cells, the
draining lymph node lymphocytes were harvested from the mice
which were pre-treated with TPA and then inoculated with EG7
tumors. The cells were then stimulated with OVA pulsed bone
marrow derived dendritic cells (BM-DC) in cultures. Results
showed that the pre-treatment with TPA induced a significantly
higher level of tumor specific IL-17 producing T cells than those
from control mice that were pre-treated with vehicle acetone
(Fig. 4b). The production of IFN-c was slightly but not significantly
affected. To determine whether the increase in IL-17 producing
lymphocytes was associated with the increased tumor growth in
TPA treated mice, wild type and IL-17R-/- mice were treated
with TPA or control acetone and then inoculated with EG7 tumor
cells. We found that the treatment with TPA significantly
enhanced tumor growth in wild type mice whereas it did not
have a significant effect on tumor growth in IL-17R-/- mice
(Fig. 4c). It is to note that the tumor growth in control IL-17R-/-
mice was inhibited compared to that in control wild type mice as
previously reported [34].
Neutralization of IL-17 inhibits the progression of DMBA/
TPA induced cutaneous carcinogenesis in mice that have
already developed tumors
Based on our results described above, which showed the
suppression of TAP induced tumor promoting inflammation in IL-
17R-/- mice, further experiments were to examine whether
neutralization of IL-17 could inhibit inflammation associated
tumor progression in mice which had already developed DMBA/
TPA induced skin tumors. Mice with skin tumors (12 weeks after
the DMBA/TPA treatment) were treated intravenously twice
(week 12 and 16) with non-replicating adenovirus encoding
neutralizing soluble IL-17R (Ad-IL-17R:Fc) or GFP as a control
(Ad-GFP). The mice were kept with TPA treatment twice a week
as described. Results showed that in the control mice which were
left untreated, the number of skin tumors increased (Fig. 5).
Neutralization of IL-17 with the administration of Ad-IL-17R:Fc
significantly inhibited the progression of tumors compared to
controls mice that were treated with Ad-GFP. The treatment with
control Ad-GFP did not have a significant effect on tumor
progression compared to mice that were left untreated (Fig. 5).
The result implicates that neutralizing IL-17 can inhibit the
progression of DMBA/TPA induced skin tumors.
Discussion
The role of IL-17 in tumor development is controversial in
implanted tumor models [14,16,35]. It appears that in induced
tumor models which are associated with inflammation, IL-17
mediated inflammation has tumor promoting effects [18,36].
However, mechanisms remain to be fully elucidated. We have
showed here that mice deficient in IL-17R are resistant to DMBA/
TPA induced carcinogenesis in the skin. The deficiency in IL-17R
enhances CD8+ T cell mediated immune surveillance and inhibits
tumor promoting inflammation in the skin. Furthermore, TPA
induced inflammation promotes the susceptibility to the growth of
implanted tumors in the skin and increases the development of
tumor specific IL-17 producing T cells. However, this TPA
induced tumor promoting effect is abrogated in IL-17R deficient
mice. Finally, we show that neutralization of IL-17 inhibits the
progression of DMBA/TPA induced skin carcinogenesis in mice
which have already developed tumors. Our data demonstrates that
IL-17 mediated inflammation promotes carcinogenesis in the skin
and targeting IL-17 may be exploited to a new therapeutic strategy
for tumors.
In DMBA/TPA induced skin carcinogenesis, IL-23 has been
shown to enhance carcinogenesis. It is postulated that IL-23
mediated up-regulation of IL-17 production is a mechanism [31].
Similar to studies in IL-17-/- mice [18], we show that the
deficiency in IL-17R render mice resistant to chemical induced
Figure 4. TPA induced promotion of tumor growth is abrogated in IL-17R-/- mice. A). TPA induced inflammation enhances tumor growth.
Wild type C57Bl/6 mice were treated epicutaneously with TPA or acetone (vehicle controls) every other day for a total of 5 applications. The mice
were then inoculated subcutaneously with EG7 tumor cells. Tumor growth was monitored (n=5). B). TPA induced inflammation increases tumor
specific IL-17 producing cells. At the end of experiments, the draining lymph node lymphocytes were collected from EG7 tumor bearing mice that
were treated with TPA or acetone. The cells stimulated with OVA pulsed BM-DC for 4 days. Concentrations of cytokines in supernatants were
measured by ELISA (n=4). Naı ¨ve T cells with OVA pulsed BM-DC (Naı ¨ve) and immune T cells with BM-DC without OVA (Neg) served as controls in the
cultures. C). TPA induced tumor promotion is abrogated in IL-17R-/- mice. Wild type or IL-17R-/- were epicutaneously treated with TPA or acetone
every other day for a total of 5 applications. The mice were then inoculated with EG7 tumor cells and tumor growth was monitored (n=5). Data are
representative of 2–3 independent experiments (mean +/2 SEM, * P,0.05).
doi:10.1371/journal.pone.0032126.g004
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susceptibility of IL-12p35-/- mice to chemical carcinogenesis. It
implicates that IL-17R mediated responses at least in part are
attribute to increased tumor growth which is caused by IL-12
deficiency. However, mechanisms for the effect require further
investigations. It is to note that in different tumor models,
especially in implanted tumor models, IL-17 can have a protective
effect against tumor development [37,38,39]. It suggests context
dependent effects of IL-17 on tumors. Our data indicate that IL-17
has tumor promoting effects in inflammation associated tumor
development in the DMBA/TPA model, which is inconsistent
with reports showing that IL-17 promotes inflammation associated
colon tumorigenesis [17,36].
In DMBA/TPA induced chemical carcinogenesis, CD8+ T cells
are primary effector cells and required for prevention of tumor
development [15]. The opposite effect of IL-17 on the infiltration
of CD11b+ myeloid cells and CD8+ T cells in the inflamed skin
implicates a novel role of IL-17 in the regulation of immune
surveillance during inflammation associated carcinogenesis in the
skin. Interestingly, similar findings have been reported in
implanted tumor models by our laboratory and others [34,40].
Numerous clinical and laboratory studies show that the presence
of macrophages is a hallmark of tumor promoting inflammation
and is associated with a poor prognosis [9,32] whereas the
presence of CD8+ T cells is associated with a good prognosis
[8,41]. The effect of IL-17 on the production of chemokines has
been well studied, which is considered to be responsible for its
effects on the regulation of myeloid cell migration [42]. We have
found that the deficiency in IL-17R reduces the expression of
chemokines KC (human IL-8 analogue) and CXCL1 in TPA
treated skin tissues, which are known to regulate the infiltration of
myeloid cells in inflammation. In contrast, chemokines CXCL9,
CXCL10 and CXCL16 which are known to regulate T cell
migration are increased [43]. The differential effects of IL-17 on
the expression of chemokines for myeloid cells and lymphocytes
provide important clues for its effects on the regulation of myeloid
cells and lymphocytes and may be important mechanisms for IL-
17 mediated tumor promoting inflammation in DMBA/TPA
induced skin tumors. Certainly, further studies are required to
determine chemokine sources and to validate whether the effect of
IL-17 on the chemokine production is associated with its effects on
the regulation of leukocyte migration and development of skin
tumors.
Depending on the functional status, myeloid cells including
neutrophils and macrophages can have pro- or anti-tumor activities
[4,44,45,46]. However, it is a common feature that the number of
myeloid derived suppressor cells (MDSC), which are defined as
CD1b/Gr-1 double positive cells in mice, is increased in cancer
patients and tumor bearing mice [47,48,49,50]. MDSC are able to
suppress anti-tumor immune responses and promote tumor growth
[47,50]. The decrease of MDSC provides a good explanation for
the suppression of DMBA/TPA induced carcinogenesis in IL-
17R-/- mice and may be an important mechanism for the role of
IL-17 in the development of tumor promoting inflammation and
immunosuppression. This is in accordance with our recent studies
showing that IL-17 stimulates the function of MDSC in tumor
bearing mice [34]. Additionally, MDSC are able to inhibit T cell
infiltration of anti-tumor T cells in tumor sites [51]. The down
regulation of MDSC in IL-17R-/- mice may contribute to the
increase of CD8+ T cells in the inflamed skin.
The effect of inflammation on tumor promotion is mediated by
complexes of mechanisms. We have found that the deficiency in
IL-17R inhibits characteristics of tumor promoting inflammation
which is mediated by the repeated treatment with TPA in the skin.
Inflammation associated hyperplasia is a pro-tumor change which
is observed in many inflammation associated tumorigenesis
[32,33]. Inflammatory infiltrates comprised of large numbers of
macrophages and granulocytes and high concentrations of
inflammatory cytokines are considered to be the primary factors
responsible for enhanced angiogenesis and cell growth [9,32].
TPA induced epidermal hyperplasia is inhibited in IL-17R-/-
mice, which is associated with significantly reduced leukocyte
infiltrations and levels of IL-1b and TNF-a. Literature shows that
a deficiency in either IL-1b or TNF-a suppresses the development
of chemical induced skin carcinogenesis [23,24]. The reduction of
IL-1b and TNF-a in IL-17R-/- mice may be part of mechanisms
for the suppression of DMBA/TPA induced skin carcinogenesis.
Cox-2/PGE2 activities are significantly reduced in TPA treated
skin of IL-17R-/- mice. Cox-2/PGE2 pathways have multiple
effects on tumor development [50,52,53,54]. Importantly, PGE2
not only promotes cell proliferation and tumor associated
angiogenesis but also induces the development of MDSC
[55,56,57]. Over expression of Cox-2 enhances whereas a defect
in Cox-2 suppresses TPA induced inflammation and DMBA/TPA
induced chemical carcinogenesis [25,26]. Additionally, our results
show that IL-17 is required for the expression of S100/A8/A9 in
Figure 5. Neutralization of IL-17 inhibits the progression of tumors in DMBA/TPA induced cutaneous carcinogenesis. Wild type
C57Bl/6 mice were topically treated once with DMBA and then twice weekly with TPA. All mice developed cutaneous tumors at 12 weeks. The mice
were divided (10 mice/group) and treated intravenously with adenovirus encoding GFP (Ad-GFP), IL-17R:Fc (Ad-IL-17R:Fc) or left untreated (Ctrl) at
week 12 and 16. All mice were continuously treated with TPA twice a week throughout the experiments. The tumor growth was monitored weekly.
Bar graph shows the mean tumor number per mouse +/2 SEM at the end of experiments (* P,0.05). Data are representative of 2 independent
experiments.
doi:10.1371/journal.pone.0032126.g005
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can induce the recruitment and differentiation of MDSC [58,59]. A
defect in S100a9 inhibits the infiltration of MDSC whereas it results
inincreasedinfiltrationofCD8+ Tcellsintumors[29].Collectively,
the inhibition of TPA induced Cox-2/PGE2 activity and S100A8/
A9 expression may be a critical mechanism for the reduction of
MDSC,increasesofCD8+ Tcellsintheskin,andthesuppressionof
DMBA/TPA induced carcinogenesis in IL-17R-/- mice.
Many cancers arise from the site of inflammation, which forms a
microenvironment for tumor growth and progression [7]. Increased
levels of IL-17 and IL-17 producing T cells have observed in human
and animal tumors [14,16,36]. A direct proof for an association of
inflammation with induction of tumor specific IL-17 producing T
cells and tumor development is not known. Our data show that pre-
existing inflammation in the skin, which is induced by repeated
treatment with TPA, increases the susceptibility of wild type mice to
implanted tumors (Fig. 4). This effect is associated with a
significantly increased level of tumor specific IL-17 producing T
cells in the draining lymph nodes. In contrast, a significant effect on
IFN-c producing cells is not observed. Importantly, the promotion
of tumor growth in TPA treated mice is abrogated in IL-17R-/-
mice. Our study provides a strong support that inflammation
induced increase of IL-17 producing T cells is a mechanism for the
increased tumor growth and that blockade of IL-17 can inhibit
inflammation mediated tumor promoting effects.
Although tumor promoting effects of inflammation have been
well documented, it remains to be explored whether targeting
inflammation can have therapeutic effects on existing tumors at
late stages. Our data show that neutralization of IL-17 in mice that
have already developed skin carcinogenesis induced by DMBA/
TPA can inhibit tumor progression (Fig. 5). It indicates a role of
IL-17 in inflammation mediated tumor progression at late phases
and suggests that blocking IL-17 could have therapeutic effects.
However, it is to note that neutralization of IL-17 can not
eliminate tumors. Mechanisms for tumor development and tumor
promoting inflammation are complicated. It is known that the
immune system in tumor bearing host is suppressed. It is possible
that IL-17 is just part of tumor promoting inflammation factors or
that blockade of IL-17 diminishes the promoting effects of
inflammation but can not restore the activity of tumor specific T
cells to eliminate tumors. Interestingly, a recent report shows that
IL-17 producing cdT cells contribute to the efficacy of anticancer
chemotherapy. A deficiency in IL-17 responses inhibits the
infiltration of cytotoxic T cells in the implanted colon tumors
[60]. Similarly, in implanted melanoma model, Th17 cells
promote the activity of cytotoxic T cells in tumors [61].
DMBA/TPA induced skin tumors are associated with persistent
inflammation which may constitute a different microenvironment
from that in implant tumors. It implicates that tumor treatment
requires multifaceted strategies which will be dependent on tumor
type, stage and microenvironment.
In summary, our studies have demonstrated that IL-17 is
required for inflammation associated tumor development in
DMBA/TPA induced skin carcinogenesis and IL-17 induces
tumor promoting inflammation through multiple interactive
mechanisms. TPA induced inflammation enhances the suscepti-
bility to tumor growth, which is associated with an increased level
of tumor specific IL-17 producing T cells. Blockade of IL-17 can
abrogate the inflammation induced susceptibility to tumor growth
and inhibit the progression of existing tumors in DMBA/TPA
induced skin carcinogenesis. Given the important role of
inflammation in tumor development, our studies implicate that
targeting IL-17 may provide novel strategies for prevention and
treatment of inflammation associated tumors.
Materials and Methods
Mice
IL-12p35-/- (C57BL/6 background) and wild type C57BL/6
mice were purchased from The Jackson Laboratory (Bar Harbor,
Maine). IL-17R-/- mice on C57BL/6 background were provided
by Amgen. IL-17R-/- mice were cross-bred to p35-/- mice to
generate double knockout mice in our laboratory. The gene
phenotype was routinely confirmed. All animal procedures were
performed according to NIH guidelines and the protocols were
approved by the Institute Animal Care and Use Committee of the
University of Alabama at Birmingham (APN: 081008302).
Cutaneous chemical carcinogenesis
Detailed protocols for DMBA/TPA induced carcinogenesis
were reported previously [15]. In the current studies, mice were
treated once with 100 mg DMBA (Sigma, St Louis, MO) in 100 ml
acetone on the shaved back skin. One week later, the DMBA
treated skin site was treated topically with 10 mg TPA in 100 ml
acetone twice weekly. The development of cutaneous tumors was
monitored every week. Tumors which were larger than 2 mm in
diameter and were present for two consecutive weeks were
counted. In compliance with IACUC requests, which were based
on tumor multiplicity and size, mice were euthanized around 26
weeks.
To examine whether neutralization of IL-17 affected the
progression of tumors in DMBA/TPA treated mice which had
already developed skin tumors, mice were treated once with
DMBA and then treated repeatedly with TPA as described above.
At 12-14 weeks after the treatment with DMBA/TPA, all mice
developed skin tumors. The mice were then divided in three
groups with similar average tumor numbers per group (10 mice/
group) and treated intravenously with non-replicating adenovirus
encoding neutralizing soluble IL-17R (Ad-IL-17R:Fc) or GFP as a
control (Ad-GFP)(10
9 pfu/mouse) or left untreated. The treatment
was repeated once 4 weeks later. This protocol has been reported
in our previous studies to neutralize IL-17 and prevent
autoimmune diseases in mice [62]. The mice remained to be
treated with TPA twice a week and tumor progression was
monitored once a week as described above.
Examination of TAP induced tumor promoting
inflammation in the skin
To examine TPA induced inflammation, back skin of mice was
shaved and treated with TPA (10 mg in 100 ml acetone) every
other day for a total of three applications. Skin samples were
harvested 24 hours after the last treatment and subjected to
analysis for inflammation.
To examine whether pre-existing chronic inflammation in-
creased the susceptibility of mice to tumor growth, mice were
topically treated on the shaved back with TPA (10 mg in 100 ml
acetone) or vehicle control (acetone) every other day for a total of
five applications. The mice were then implanted subcutaneously in
the TAP treated area with a mouse lymphoma cells line EG7 (EL4
transfected with OVA, E.G7-OVA, CRL-2113, ATCC) at
4610
6/mouse one day after the last treatment with TPA. The
growth of tumors was measured every three days by using an
engineer’s micrometer [34].
Analysis of T cell cytokine production
The draining lymph nodes of EG7 tumor bearing mice were
collected at the end of experiments and cell suspensions were
prepared as described [34]. Bone marrow derived dendritic cells
(BM-DC) were generated and pulsed with OVA for 24 hours as
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(2610
6/ml) were stimulated with OVA-pulsed BM-DC (2610
5/
ml) for 4 days. Culture supernatants were harvested and measured
for concentrations of cytokines by ELISA as described [34]. Naı ¨ve
T cells with OVA pulsed BM-DC (Naı ¨ve) and immune T cells with
BM-DC without OVA (Neg) served as controls in the cultures.
Immunohistochemical staining of skin tissues
Immunohistochemical staining of tissue sections was described in
our previous studies [63]. Frozen tissue sections (5 mm) were applied
for staining of CD8 and CD11b positive cells. Paraffin embedded
sections (6 mm) were applied for staining of PCNA and Cox-2. The
antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA), Cayman Chemical (Ann Arbor, MI) and BD-
Biosciences (San Diego, CA). Pictures were taken microscopically
(206objective) with a digital camera (Olympus). Positive cells were
countedin10 fieldsof each group. Average numbers of positive cells
per field were calculated and the difference between groups was
analyzed statistically. The thickness of epidermis of skin sections was
measured with the ImagePro Plus software.
Analysis of PGE2 by enzyme immunoassay
The concentration of PGE2 in the TPA treated skin tissues was
measured by using a prostaglandin E2 EIA kit according to the
manufacturer’s instructions (Cayman Chemical, Ann Arbor, MI).
Briefly, skin samples were homogenized in the buffer provided by
the kit and centrifuged at 11,000 rpm for 15 min. The
concentration of PGE2 in supernatants was determined and
normalized to the protein concentration in supernatants.
Western blot
Western blots were conducted as reported in our previous
studies [64]. To detect S100A8 and A9 proteins, skin tissues were
harvested and lysed in the RIPA buffer. Equal amounts of proteins
samples were loaded onto 7.5% SDS-PAGE and then transferred
to nitrocellulose membranes. The membranes were probed with
anti-S100A8, A9 or GAPDH antibodies. After wash, the blots
were incubated with appropriate horseradish peroxidase-linked
secondary antibodies. Protein bands were revealed by enhanced
chemiluminescence (ECL) system (Pierce biotechnology, Rock-
ford, IL). Blots were photographed with Bio-Rad gel documen-
tation system and analyzed using Quantity one 1-D Analysis
Software (Bio-Rad Laboratories, Hercules, CA).
Detection of cytokines in skin tissues
Skin tissues were homogenized in the RIPA buffer. Concentra-
tions of IL-1b and TNF-a in the lysates were measured by cytokine
specific ELISA using commercial assay kits according to the
manufacturer’s instructions (Invitrogen). Concentrations of cyto-
kines were normalized to protein concentrations in each sample.
Real Time RT-PCR
The expression of mRNA for chemokines and inflammatory
mediators was quantified by real time RT-PCR as described in our
previous report [23]. Briefly, Skin tissues were homogenized in
TRIzol and total RNA was isolated according to the manufac-
ture’s instructions (GibcoBRL). Real time TR-PCR was per-
formed with iQ SYBRO Green Supermix Kit in a MyiQ real time
qPCR system according to the manufacture’s instructions (Bio-
Rad). The expression level of cytokines was normalized to the
house-keeping gene GAPDH in each sample. The sequences for
primers were The sequences for primers were The sequences for
primers were : CXCL9: forward, 59-CCGCTGTTCTTTTC-
CTTTTG-39, reverse, 59-TCCCCCTCTTTTGCTTTTTC-3;
S100A9: forward, 59-TCATCGACACCTTCCATCAA-39, re-
verse, 59-GATCAACTTTGCCATCAGCA-39; S100A8: forward,
59-ACAATGCCGTCTGAACTGG-39, reverse, 59-CTCTGCT-
ACTCCTTGTGGCTGTCT-39; CXCL1: forward, 59-GCTG-
GGATTCACCTCAAGAAC-39, reverse, 59-TGGGGACACCT-
TTTAGCATC-39; CXC16: forward, 59-ATGAGAAACAGCAA-
GATGACAG-39, reverse, 59-CAGTGAGGAAGAAGACAAT-
GG -39; CXCL10: forward, 59-CGTCATTTTCTGCCT-
CATCC-39, reverse, 59-CAGACATCTCTGCTCATCATTC-
39; KC: forward, 59-GATTCACCTCAAGAACATCCAG-39,
reverse, 59-TGGGGACACCTTTTAGCATC-39; IL-1b: forward,
59-ACAGCAGCACATCAACAAGAG-39, reverse, 59-ATGG-
GAACGTCACACACCAG-39; GApDH: forward, 59-AATGGT-
GAAG GTCGGTGTGAAC-39, reverse, 59-GAAGATGGT-
GATGGGCTTCC-39.
Statistical analysis
All data are presented as means +/2 SEM. Two-tailed
Student’s t-test was applied for statistical analysis with P,0.05
being considered statistically significant.
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